Xellia Pharmaceuticals Inc. Sustainability Profile
Xellia Pharmaceuticals Inc., a leading global provider of specialty pharmaceuticals, is headquartered in the United States. Founded in 1908, the company has established a strong presence in the development and manufacturing of anti-infective and injectable products, primarily focusing on critical care and hospital settings. With operational facilities in Europe and North America, Xellia is renowned for its expertise in producing high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. The company’s core offerings include a range of injectable antibiotics and antifungal medications, distinguished by their efficacy and safety profiles. Xellia's commitment to innovation and quality has positioned it as a trusted partner in the healthcare industry, achieving notable milestones such as regulatory approvals and strategic collaborations. With a robust market presence, Xellia Pharmaceuticals continues to advance its mission of improving patient outcomes worldwide.
DitchCarbon Score
How does Xellia Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Xellia Pharmaceuticals Inc.'s score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Xellia Pharmaceuticals Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of reported figures. The company is classified as a current subsidiary and does not inherit emissions data from a parent organisation. In terms of climate commitments, Xellia Pharmaceuticals has not outlined any specific reduction targets or initiatives, nor does it participate in recognised frameworks such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). This lack of publicly available data suggests that the company may still be in the early stages of developing its climate strategy and emissions reporting. As the pharmaceutical industry increasingly prioritises sustainability, Xellia Pharmaceuticals may benefit from establishing clear emissions reduction targets and engaging in industry-standard climate initiatives to enhance its environmental performance and transparency.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 7,256,000 | 0,000,000 |
| Scope 2 | 16,258,000 | 00,000,000 |
| Scope 3 | 127,920,000 | 000,000,000 |
How Carbon Intensive is Xellia Pharmaceuticals Inc.'s Industry?
How Carbon Intensive is Xellia Pharmaceuticals Inc.'s Location?
Xellia Pharmaceuticals Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Xellia Pharmaceuticals Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
